Background/objective: Osimertinib, an EGFR-targeted agent approved for metastatic NSCLC, shows promise for triple-negative breast cancer due to EGFR overexpression in aggressive tumors. However, oral administration limits tumor delivery and causes systemic side effects. This study aimed to develop chitosan-coated PLGA...
Iman M. Alfagih, Maryam Alfagih, Alanood S. Almurshedi et al.· Pharmaceutics· 0 citations
Melanoma remains a highly lethal malignancy, often associated with limited therapeutic efficacy and substantial systemic toxicity caused by conventional chemotherapy. Triptolide (TP) exhibits potent antitumor activity, but its clinical application is limited by poor aqueous solubility and a narrow therapeutic window. I...
Gen-Ying Zhuang, Yan-Li Chen, Xiu-Li Gao et al.· BioMed Research Internationa...· 0 citations
In an in vivo model of breast cancer, intraductal H-NPs reduced tumor incidence and volume compared to a drug solution, and increased the mammary tissue-to-plasma ratio of paclitaxel by 105-fold, supporting an improved tissue retention, support H-NPs as promising platforms for localized breast cancer therapy.
J. S. Passos, G. C. Salata, G. B. de Melo et al.· International journal of pha...· 0 citations
The clinical translation of Pterostilbene, a neuroactive stilbene with broad therapeutic potential, is hampered by its poor aqueous solubility and insufficient brain accumulation. To address these limitations, we developed a folate receptor-targeted polymeric micelle system (F–Pt/M) using poly (ethylene glycol)-block-p...
Xiao-Bo Yang, Yu-Ze Sun, Huan Jin et al.· Neurotherapeutics· 0 citations
Chemotherapy remains the primary treatment for advanced lung squamous cell carcinoma (LUSC); however, its severe toxic side effects significantly limit therapeutic efficacy. There is an urgent clinical need to integrate molecular targeting with chemotherapy to enhance treatment outcomes. Consequently, this study develo...
Xing Wei, Lei-Yu Cao, Yan Gao et al.· Clinical and Experimental Me...· 0 citations
Findings provide proof-of-concept evidence that PSMA-targeted DUPA-PEG LIPOs can facilitate Talazoparib delivery and, particularly in combination with BI 2536, may enhance antitumor activity in PCa models.
Miguel Ferreira, Neelum Aziz Yousafzai, Lital Ben Naim et al.· Pharmaceutics· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.